亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南偉都化工有限公司  

醫藥原料藥和醫藥中間體

搜索
新聞中心
產品分類
  • 暫無分類
聯系方式
  • 聯系人:姚銳
  • 電話:0531-88873471
  • 郵件:wedochem@gmail.com
  • 傳真:0531-88873470
  • QQ:1783747865
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 二對禁發 甲苯磺酸拉帕替尼
二對禁發 甲苯磺酸拉帕替尼
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 偉都化工
型號 388082-78-8
規格 99%
過期 長期有效
更新 2013-11-25 11:40
 
詳細信息
二對禁發 甲苯磺酸拉帕替尼 388082-78-8 
英文名  Lapatinib ditosylate 
別名  N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) 
產品名稱  二對禁發 甲苯磺酸拉帕替尼; N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-(((2-(甲磺酰基)乙基)氨基)甲基)-2-呋喃基)-4-喹唑啉胺二對禁發 甲苯磺酸鹽   
分子式  C29H26ClFN4O4S.2(C7H8O3S) 
分子量  925.46 
CAS 登錄號  388082-78-8
抗腫瘤原料藥
©2025 濟南偉都化工有限公司 版權所有   技術支持:化工網   訪問量:22774  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |